Harpoon Therapeutics, Inc. stock is up 88.93% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 December’s closed higher than November. 100% of analysts rate it a buy.
Harpoon Therapeutics, Inc. engages in the development of a novel class of T cell engagers that harness the power of the body's immune system. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors.